Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NRDC wants FDA to act on BPA

This article was originally published in The Tan Sheet

Executive Summary

The Natural Resources Defense Council requests a court order compelling FDA to act on the council's petition to ban the use of bisphenol A in food packaging and other materials likely to contact food. NRDC, which filed the complaint June 29 in the U.S. Court of Appeals for the D.C. Circuit, petitioned FDA in October 2008 to prohibit BPA, a hormone-disrupting chemical, in food packaging. FDA officials expressed concern about the effects of early life exposure to BPA on brain development and the prostate gland of fetuses, infants and children (1"The Tan Sheet" Jan. 25, 2010). When the agency noted that a National Institutes of Health's National Toxicology Program expressed "concern for effects of the substance on the brain, behavior and prostate gland in fetuses, infants and children at current human exposures," makers of infant formula sought substitutes to BPA use in can linings (2"The Tan Sheet" March 1, 2010)

You may also be interested in...

FDA Shift On BPA May Tighten Squeeze On Infant Formula Manufacturers

FDA's shift in position regarding the safety of bisphenol A likely will expedite the trend toward BPA-free packaging among infant formula marketers, even though existing science does not demonstrate a proven threat to babies and children

Germany's OTC Market in 2019: Stagnation Overall, Online Growth Continues

A weak cough and cold season in Germany last winter held back OTC sales growth in 2019, according to IQVIA, while the country's online pharmacy channel continued to expand. 

Stockwatch: Choppy Waters For Teva And Bausch

After most of the big pharmaceutical companies reported their full-year 2019 financial results, the second month of earnings season brings the long tail of smaller biotech companies and the generic pharmaceutical companies. There is more than one uncomfortable parallel from the former in the reports of the latter.







Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts